Invention of novel 3-aminopiperidin-2-ones as calcitonin gene-related peptide receptor antagonists.

A novel series of 3-amino-piperidin-2-one-based calcitonin gene-related peptide (CGRP) receptor antagonists was invented based upon the discovery of unexpected structure-activity observations. Initial exploration of the structure-activity relationships enabled the generation of a moderately potent lead structure (4). A series of modifications, including ring contraction and inversion of stereocenters, led to surprising improvements in CGRP receptor affinity. These studies identified compound 23, a structurally novel potent, orally bioavailable CGRP receptor antagonist.

Informations de copyright

Copyright © 2024. Published by Elsevier Ltd.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Ian M. Bell reports a relationship with Merck & Co Inc that includes: employment and equity or stocks. Donnette D. Staas reports a relationship with Merck & Co Inc that includes: employment and equity or stocks. Christopher S. Burgey reports a relationship with Merck & Co Inc that includes: employment and equity or stocks. James Z. Deng reports a relationship with Merck & Co Inc that includes: employment and equity or stocks. Anthony W. Shaw reports a relationship with Merck & Co Inc that includes: employment and equity or stocks. Heather Stevenson reports a relationship with Merck & Co Inc that includes: employment and equity or stocks. Craig A. Stump reports a relationship with Merck & Co Inc that includes: employment and equity or stocks. C. Blair Zartman reports a relationship with Merck & Co Inc that includes: employment and equity or stocks. Eric L. Moore reports a relationship with Merck & Co Inc that includes: employment and equity or stocks. Scott D. Mosser reports a relationship with Merck & Co Inc that includes: employment and equity or stocks. Rebecca B. White reports a relationship with Merck & Co Inc that includes: employment and equity or stocks. Christopher A. Salvatore reports a relationship with Merck & Co Inc that includes: employment and equity or stocks. Mark E. Fraley reports a relationship with Merck & Co Inc that includes: employment and equity or stocks. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.